Related Experiment Video

Updated: Sep 12, 2025

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays
07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

8.0K

CircRNAs: emerging players in tyrosine kinase inhibitor resistance mechanisms in solid tumors

Alireza Soleimani1, Soudeh Ghafouri-Fard2

  • 1Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Molecular Biology Reports
|August 6, 2025
PubMed

Insights

Circular RNAs (circRNAs) drive tyrosine kinase inhibitor (TKI) resistance in solid tumors by affecting key cancer pathways. Targeting circRNAs offers a promising strategy to overcome drug resistance and improve cancer treatment outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • RNA Therapeutics

Background:

  • Tyrosine kinase inhibitors (TKIs) have transformed cancer therapy for various malignancies.
  • Acquired resistance to TKIs remains a significant clinical obstacle, leading to treatment failure.
  • Circular RNAs (circRNAs) are emerging as critical regulators in cancer progression and drug resistance.

Purpose of the Study:

  • To review the current understanding of circRNAs' role in mediating TKI resistance in solid tumors.
  • To elucidate the molecular mechanisms by which circRNAs contribute to TKI resistance.
  • To explore the potential of circRNA-based strategies for overcoming TKI resistance in clinical settings.

Main Methods:

  • Comprehensive literature review of studies investigating circRNAs and TKI resistance in solid tumors.
  • Analysis of molecular pathways influenced by circRNA dysregulation in the context of TKI resistance.
  • Evaluation of current and emerging RNA-targeted technologies for therapeutic applications.

Main Results:

  • CircRNAs are dysregulated in TKI-resistant solid tumors.
  • CircRNAs modulate critical pathways including apoptosis, autophagy, and epithelial-mesenchymal transition.
  • Alternative kinase activation is influenced by circRNAs, contributing to resistance mechanisms.

Conclusions:

  • CircRNAs play a pivotal role in the development of TKI resistance in solid tumors.
  • Understanding circRNA functions provides insights into novel therapeutic targets.
  • RNA-targeted therapies hold promise for overcoming TKI resistance and improving patient outcomes.
Keywords:
CancerCircRNADrug resistanceMiRNANon-coding RNATyrosine kinase inhibitor

More Related Videos

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

15.0K
Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.9K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
14.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.8K